title: [Effectiveness of N-acetylcysteine in the treatment of schizophrenia].
abstract: Oxidative stress and neuroinflammation have recently been focused on the pathological hypotheses of schizophrenia. N-acetylcysteine (NAC) is a precursor of endogenous antioxidant glutathione and has antioxidant, anti-inflammatory, and neuroprotective properties. NAC is widely available as an over-the-counter nutritional supplement. Increasing lines of evidence suggest that NAC is effective for various mental disorders. In randomized controlled trials, treatment with NAC as an add-on to antipsychotics showed beneficial effects and safety profiles in patients with chronic schizophrenia. The results of a recent preclinical study using a neurodevelopmental model of schizophrenia suggest that NAC may have promising effects in an early stage of schizophrenia and an at-risk mental state. However, there is little clinical evidence for the efficacy and safety of NAC at these stages of schizophrenia. In this review, we summarize the evidence regarding the effectiveness of NAC for the treatment of schizophrenia and its prodromal stage. We also introduce the preliminary results of our research on NAC.
authors.forename: Nobumi
authors.initials: N
authors.lastname: Miyake
authors.forename: Seiya
authors.initials: S
authors.lastname: Miyamoto
mesh_terms: D000111:Acetylcysteine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D005978:Glutathione; D006801:Humans; D017628:Microglia; D018696:Neuroprotective Agents; D018384:Oxidative Stress; D012559:Schizophrenia / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D018696:Neuroprotective Agents; D005978:Glutathione; D000111:Acetylcysteine